INVO, EZGO and WISA among pre-market losers
- Losers: Lithium Americas Corp (LAC) down 24% due to plans for a 55M-share offering. NRX Pharmaceuticals (NRXP) down 22% after announcing a proposed public stock offering. Canaan (CAN) down 22% following a $300M mixed shelf offering filing. Iczoom Group (IZM) down 12%. INVO Bioscience (INVO) down 12%. BYND Cannasoft Enterprises (BCAN) down 11%. WiSA Technologies (WISA) down 9%. Infosys Ltd (INFY) down 8% due to mixed Q4 results. EZGO Technologies Ltd (EZGO) down 6%. Rentokil Initial Plc. (RTO) down 7%. TRACON Pharmaceuticals (TCON) down 6%. Indonesia Energy Corp Ltd (INDO) down 6%. Organovo Holdings (ONVO) down 5%.
- Pre-market losers & stocks: EZGO Technologies partners with Woteam New Energy for Southeast Asian market exploration. WiSA Technologies rises on announcing fourth HDTV/PTV license with a major TV brand. Financial information available for EZGO Technologies. Seeking Alpha’s Quant Rating on INVO BioScience. Historical earnings data provided for INVO BioScience.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on RTO
About RTO
About the author
Reasons to Consider Rentokil Initial (RTO) as a New Investment Opportunity
Zacks Rank Upgrade: Rentokil Initial PLC has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, showing a strong correlation with near-term stock movements, making Rentokil a solid candidate for potential market-beating returns.
Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Rentokil has increased by 0.3%, reflecting analysts' growing confidence in the company's earnings potential.
Historical Performance: The Zacks Rank system has a proven track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988, highlighting the effectiveness of tracking earnings estimates for investment decisions.
Citigroup Confirms Buy Recommendation for Rentokil Initial plc - Depositary Receipt (RTO)
Citigroup's Recommendation: On October 24, 2025, Citigroup reiterated a Buy recommendation for Rentokil Initial plc - Depositary Receipt (NYSE:RTO), despite an average one-year price target suggesting a 4.39% downside from its current price of $29.31/share.
Projected Revenue and EPS: Rentokil Initial plc is projected to have an annual revenue of $6,094 million, reflecting a 10.12% increase, with a non-GAAP EPS forecast of 0.28.
Fund Sentiment: There are 471 funds reporting positions in Rentokil Initial, with a 5.99% decrease in the number of owners over the last quarter, while total shares owned by institutions increased by 6.46% to 393,907K shares.
Shareholder Activity: Notable changes in shareholder positions include significant increases by AEPGX and OAKIX, while BLACKROCK EQUITY DIVIDEND FUND reported a decrease in shares owned, indicating varied investment strategies among major funds.
